GSK to pay $70 million to settle whistleblower lawsuit Pfizer and Sanofi also settling Zantac cases Boehringer Ingelheim faces trial, denies wrongdoing Oct 9 (Reuters) - GSK (GSK.L), opens new tab ...

Not too long ago, pharmaceutical giant Astrazeneca reached a £200bn valuation—one of only a few London-listed FTSE 100 ...

GSK has struck a $2.2 billion agreement to settle the vast majority of U.S. lawsuits filed against it over claims its Zantac heartburn remedy causes cancer. The British drugmaker's settlement with ...

GSK Plc said it will pay as much as $2.2 billion to resolve about 80,000 US court cases related to allegations that its old reflux medication Zantac was contaminated with a suspected carcinogen ...

GSK's shares were priced at 1,358 pence this morning, a far cry from the middle of 2013 when the stock was trading at a little below 1,750 pence. Last year's corruption scandal in China ...

GSK has stopped (PDF) development of one of the lead programs from its $2.1 billion Affinivax takeover, axing a phase 2 pneumococcal 24-valent vaccine candidate for adults in favor of a ...

UK pharmaceutical giant GlaxoSmithKline (GSK) has announced a five year collaboration with Cambridge University despite claims that a discontinued version of its heartburn drug causes cancer. GSK is ...

Regulators narrowed the targeted age group for RSV vaccines Demand for RSV vaccines has fallen by up to two-thirds GSK maintains market lead despite reduced sales Some independent pharmacists said ...

GSK’s blockbuster hopes for depemokimab remain on track after the investigational long-acting asthma treatment has also been shown to reduce nasal polyps in a pair of phase 3 trials. The ANCHOR ...